NO314684B1 - Anvendelse av selegilin til fremstilling av farmasöytiske preparater for behandling av epileptiske tilstander - Google Patents
Anvendelse av selegilin til fremstilling av farmasöytiske preparater for behandling av epileptiske tilstander Download PDFInfo
- Publication number
- NO314684B1 NO314684B1 NO19970607A NO970607A NO314684B1 NO 314684 B1 NO314684 B1 NO 314684B1 NO 19970607 A NO19970607 A NO 19970607A NO 970607 A NO970607 A NO 970607A NO 314684 B1 NO314684 B1 NO 314684B1
- Authority
- NO
- Norway
- Prior art keywords
- selegiline
- treatment
- epileptic
- effect
- preparation
- Prior art date
Links
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 title claims abstract description 23
- 229960003946 selegiline Drugs 0.000 title claims abstract description 22
- 230000001037 epileptic effect Effects 0.000 title claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 title claims 2
- 238000002360 preparation method Methods 0.000 title description 3
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- 206010010904 Convulsion Diseases 0.000 claims description 17
- 230000036461 convulsion Effects 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000001629 suppression Effects 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 7
- 230000003556 anti-epileptic effect Effects 0.000 abstract description 5
- 230000000694 effects Effects 0.000 description 11
- 239000001961 anticonvulsive agent Substances 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 206010015037 epilepsy Diseases 0.000 description 7
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000001773 anti-convulsant effect Effects 0.000 description 5
- 230000001535 kindling effect Effects 0.000 description 5
- 230000001960 triggered effect Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 229940125681 anticonvulsant agent Drugs 0.000 description 4
- 210000004727 amygdala Anatomy 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000004498 neuroglial cell Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- 229960000623 carbamazepine Drugs 0.000 description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- NNGAJMDJKNFZAE-UHFFFAOYSA-N n-methyl-2-phenyl-n-prop-1-ynylpropan-2-amine Chemical class CC#CN(C)C(C)(C)C1=CC=CC=C1 NNGAJMDJKNFZAE-UHFFFAOYSA-N 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229960002036 phenytoin Drugs 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102100028116 Amine oxidase [flavin-containing] B Human genes 0.000 description 1
- 101710185931 Amine oxidase [flavin-containing] B Proteins 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010061334 Partial seizures Diseases 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 230000002059 anti-epileptogenic effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000008579 epileptogenesis Effects 0.000 description 1
- 201000007186 focal epilepsy Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000007387 gliosis Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000001730 monoaminergic effect Effects 0.000 description 1
- 201000003152 motion sickness Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4428444A DE4428444A1 (de) | 1994-08-11 | 1994-08-11 | Verwendung von Selegilin zur Behandlung von epileptischen Erkrankungen |
| PCT/DE1995/000981 WO1996004897A1 (de) | 1994-08-11 | 1995-07-27 | Verwendung von selegilin zur behandlung von epileptischen erkrankungen |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO970607L NO970607L (no) | 1997-02-10 |
| NO970607D0 NO970607D0 (no) | 1997-02-10 |
| NO314684B1 true NO314684B1 (no) | 2003-05-05 |
Family
ID=6525440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19970607A NO314684B1 (no) | 1994-08-11 | 1997-02-10 | Anvendelse av selegilin til fremstilling av farmasöytiske preparater for behandling av epileptiske tilstander |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US5952388A (et) |
| EP (1) | EP0774961B1 (et) |
| JP (1) | JP3922307B2 (et) |
| CN (1) | CN1081918C (et) |
| AT (1) | ATE239458T1 (et) |
| AU (1) | AU691316B2 (et) |
| BR (1) | BR9508531A (et) |
| CA (1) | CA2197176C (et) |
| CZ (1) | CZ285681B6 (et) |
| DE (2) | DE4428444A1 (et) |
| DK (1) | DK0774961T3 (et) |
| EE (1) | EE04176B1 (et) |
| ES (1) | ES2199252T3 (et) |
| HU (1) | HU223529B1 (et) |
| MY (1) | MY116362A (et) |
| NO (1) | NO314684B1 (et) |
| PL (1) | PL188040B1 (et) |
| PT (1) | PT774961E (et) |
| RU (1) | RU2155584C2 (et) |
| SK (1) | SK283205B6 (et) |
| TR (1) | TR199500984A2 (et) |
| TW (1) | TW448044B (et) |
| WO (1) | WO1996004897A1 (et) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19630035A1 (de) * | 1996-07-25 | 1998-01-29 | Asta Medica Ag | Tramadol Multiple Unit Formulierungen |
| DE19716905C1 (de) * | 1997-04-22 | 1998-08-27 | Iip Inst Fuer Ind Pharmazie Fo | Stabile, wäßrige Lösung auf der Grundlage von Selegilin und Vorrichtung zu ihrer Verabreichung |
| DE19743323C2 (de) * | 1997-09-30 | 2000-05-25 | Iip Inst Fuer Ind Pharmazie Fo | Feste Arzneimittelzusammensetzung auf der Grundlage von Selegilin |
| ATE427745T1 (de) * | 2001-11-05 | 2009-04-15 | Krele Pharmaceuticals Llc | Zusammensetzungen und verfahren zur erhíhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmus |
| GB201715919D0 (en) * | 2017-09-29 | 2017-11-15 | Gw Res Ltd | use of cannabinoids in the treatment of epilepsy |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5192808A (en) * | 1990-08-31 | 1993-03-09 | Deprenyl Animal Health, Inc. | Therapeutic effect of L-deprenyl in the management of pituitary-dependent hyperadrenocorticism (cushing's disease) |
| WO1992017169A1 (en) * | 1991-04-04 | 1992-10-15 | The University Of Toronto Innovations Foundation | Use of deprenyl to maintain, prevent loss, or recover nerve cell function |
| US5648087A (en) * | 1993-03-09 | 1997-07-15 | Sanofi Sante Nutrition Animale | Anaesthetic pharmaceutical composition comprising a general anaesthetic and selegiline |
| US5462740A (en) * | 1993-09-17 | 1995-10-31 | Athena Neurosciences, Inc. | Rectally-administered, epileptic-seizure-inhibiting composition |
-
1994
- 1994-08-11 DE DE4428444A patent/DE4428444A1/de not_active Withdrawn
-
1995
- 1995-07-17 TW TW084107378A patent/TW448044B/zh not_active IP Right Cessation
- 1995-07-27 RU RU97104062/14A patent/RU2155584C2/ru not_active IP Right Cessation
- 1995-07-27 AU AU29760/95A patent/AU691316B2/en not_active Ceased
- 1995-07-27 EE EE9700068A patent/EE04176B1/et not_active IP Right Cessation
- 1995-07-27 WO PCT/DE1995/000981 patent/WO1996004897A1/de active IP Right Grant
- 1995-07-27 AT AT95925732T patent/ATE239458T1/de not_active IP Right Cessation
- 1995-07-27 CN CN95194569A patent/CN1081918C/zh not_active Expired - Fee Related
- 1995-07-27 CA CA002197176A patent/CA2197176C/en not_active Expired - Fee Related
- 1995-07-27 HU HU9700405A patent/HU223529B1/hu not_active IP Right Cessation
- 1995-07-27 ES ES95925732T patent/ES2199252T3/es not_active Expired - Lifetime
- 1995-07-27 JP JP50690596A patent/JP3922307B2/ja not_active Expired - Fee Related
- 1995-07-27 CZ CZ97407A patent/CZ285681B6/cs not_active IP Right Cessation
- 1995-07-27 SK SK199-97A patent/SK283205B6/sk not_active IP Right Cessation
- 1995-07-27 PT PT95925732T patent/PT774961E/pt unknown
- 1995-07-27 DK DK95925732T patent/DK0774961T3/da active
- 1995-07-27 US US08/776,931 patent/US5952388A/en not_active Expired - Fee Related
- 1995-07-27 DE DE59510674T patent/DE59510674D1/de not_active Expired - Fee Related
- 1995-07-27 PL PL31829295A patent/PL188040B1/pl not_active IP Right Cessation
- 1995-07-27 EP EP95925732A patent/EP0774961B1/de not_active Expired - Lifetime
- 1995-07-27 BR BR9508531A patent/BR9508531A/pt not_active Application Discontinuation
- 1995-07-31 MY MYPI95002228A patent/MY116362A/en unknown
- 1995-08-09 TR TR95/00984A patent/TR199500984A2/xx unknown
-
1997
- 1997-02-10 NO NO19970607A patent/NO314684B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6455590B1 (en) | Deprenyl compounds for treatment of glaucoma | |
| US20090131508A1 (en) | Use of 2-Oxo-1-Pyrrolidone Derivatives for the Preparation of a Drug | |
| UA119445C2 (uk) | Нові композиції для лікування неврологічних розладів | |
| USRE49351E1 (en) | Cytoprotective agent | |
| AU2002340971B2 (en) | Use of 2-oxo-1-pyrrolidine derivatives for the treatment of dyskinesia and movement disorders | |
| US20210161932A1 (en) | Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist | |
| Kaur et al. | Differential effects of intrastriatal and intranigral injections of glutamate antagonists on motor behaviour in the reserpine-treated rat | |
| NO314684B1 (no) | Anvendelse av selegilin til fremstilling av farmasöytiske preparater for behandling av epileptiske tilstander | |
| CN102026640A (zh) | 用于治疗听力损害的sGC刺激剂、sGC活化剂及其组合 | |
| US9855277B2 (en) | Use of 5H-dibenz/b,f/azepine-5-carboxamide derivatives for treating fibromyalgia | |
| Gagnaire et al. | The Ototoxic Effects Induced in Rats by Treatment for 12 Weeks with 2‐Butenenitrile, 3‐Butenenitrile and cis‐2‐Pentenenitrile | |
| WO2012098000A1 (en) | Neramexane for the treatment or prevention of tinnitus related with stress or acute hearing loss | |
| KR101818395B1 (ko) | 난청의 예방 또는 치료용 조성물 | |
| KR20170045559A (ko) | 난청의 예방 또는 치료용 조성물 | |
| MXPA97001031A (en) | Utilization of selegiline for the treatment of epilepti diseases | |
| EP0489640B1 (fr) | Utilisation de phényléthanolaminotétralines pour la préparation de médicaments antidépressifs et anti-stress | |
| US20220233503A1 (en) | Methods of treating sepsis with synaptic vesicle 2a and/or 2b binding chemical entities | |
| CN107569577A (zh) | 一种药物组合物在制备治疗三叉神经痛的药物中的应用 | |
| UA118785C2 (uk) | Композиції для лікування механічних пошкоджень нервів | |
| CN116637113A (zh) | 棕榈碱在制备治疗或预防铂类或氨基糖苷类药物引起的耳毒性的药物中的应用 | |
| WO2000066105A9 (en) | Treatment of epilepsy with imino sugars | |
| JP2002265355A (ja) | 糖尿病由来虚血性心疾患の治療及び／または予防剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |